A call for action: IAOCR urges CROs support more high throughput research centres in UK

By Flora Southey contact

- Last updated on GMT

(Image: Getty/FabioBalb)
(Image: Getty/FabioBalb)
CRO executives are being urged to write letters of support for more high throughput clinical research centres in the UK, which could help attract foreign investment, says IAOCR.

IAOCR, an accrediting body for the clinical research industry, has made an “urgent call” ​for letters of support from chief executives of clinical research organisations (CROs) to the UK Department of Health and Social Care, which is due to consider a funding application for more high throughput clinical research centres in the UK.

According to the IAOCR, additional high throughput centres in the UK’s national health services (NHS), would benefit patients, industry, and “present a crucial element in making the UK competitive.”

“These centres will be staffed with clinical professionals that are competent in conducting clinical trials and whose work is dedicated entirely to this purpose [and] accredited through a system of independent verification of competence and provide a benchmark for the clinical trial industry,” ​IAOCR CEO Jacqueline Johnson North told us.

The setting up of these centres could also help improve patient outcomes, cost efficiencies, and attract foreign investment, she added.

According to IAOCR, industry support would “provide invaluable backing” ​for the initiative, as well help raise the profile for CROs in the UK at a parliamentary level: “The role of CROs and the funding they bring to the NHS through clinical trials is largely unrecognised within UK parliament.”

Brexit: An opportunity?

With the UK planning its withdrawal​ from the European Union, Johnson North said now is the time for the UK to present itself as a “country of choice” ​for the conduct of clinical trials.

“This can be achieved through a combination of initiatives which result in trials being set-up and conducted efficiently and effectively, making the UK a centre of excellence and securing the industry’s future,” ​she told us.

The UK needs to think about their role in the international clinical research industry, and what this could be following Brexit; there is huge potential, said North.

“The UK can use this opportunity to set new standards,” ​she added.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more